HCLF 2021 Conference, Medical/Scientific Sessions

October 7th and 8th, 2021 (Virtual)

Session Day 1: Thursday, October 7th from 10 am to 1 pm eastern time

10 am eastern

  • Welcome from Marc Stadtmauer, HCLF Board President

  • Welcome from Dr. Michael Grever, HCLF Scientific Committee Chair; The Ohio State University, USA

Presentations from 2020 HCLF/SASS Grant Recipients

Session Moderator:

  • Dr. Sascha Dietrich, University Hospital Heidelberg, Germany

10:10 am eastern

  • Dr. Fabienne Meier-Abt, Universitätsspital Zürich, Switzerland; Presentation title: Novel Methods for the Characterization of HCL and Other B Cell Lymphomas

10:35 am eastern

  • Dr. Evgeny Arons, NIH, USA; Presentation title: Whole Exome Sequencing Study of HCL and HCLv Genomes: Preliminary Results

11:05 am eastern

  • Dr. Versha Banerji, Manitoba CancerCare, Canada; Presentation title: Using Multiple Databases to Understand Sex Differences in Leukemia

Break (5 min.)

11:30 am eastern

  • Dr. Christopher Oakes, The Ohio State University, USA; Presentation title: Identification of Novel Molecular Subtypes of the Hairy Cell Leukemia Variant Using Epigenetics

12:00 pm eastern

  • Dr. Clive Zent, University of Rochester, USA; Presentation title: Immune Microenvironment of Indolent B Cell Splenic Lymphomas: Role in Diagnosis and Treatment

12:30 pm eastern

Case Study Presentation

  • Dr. Michael Grever, The Ohio State University, USA

12:40 pm eastern

Announcements

  • HCL2025 Grantees

1:00 pm eastern

Closing

Session Day 2: Friday, October 8th from 10 am to ~1:15 pm eastern time

10 am eastern: Welcome back from Dr. Michael Grever, The Ohio State University, USA

…

10:00 am eastern

COVID-19 and Vaccine Response

This session will last about 1 hour.

Session Moderator:

  • Dr. Tim Call, Mayo Clinic, USA

Session Description: Following a presentation of case studies, Dr. Call will facilitate discussion about recommendations for HCL treatment and how the ongoing pandemic factors in decision making.

Presentations from investigators with data on HCL patients and COVID vaccine response:

  • Dr. Larry Saltzman, Leukemia & Lymphoma Society (LLS) (10 min.)

  • Dr. Judit Demeter, Semmelweis University Medical School, Hungary (10 min.)

  • Dr. Robert J. Kreitman, NIH, USA (10 min.)

Moderated discussion and next steps.

…

11 am eastern

Optimal Frontline: Purine-analog based vs. Targeted Therapy

This session will last about 1 hour.

Session Moderator:

  • Dr. Michael Grever, The Ohio State University, USA

Session Description: Following brief data presentations, Dr. Grever will facilitate a conversation about non-chemotherapy options, such as Vemurafenib, compared to Purine nucleoside analogues (PNA). While we are fortunate to have had agents introduced that have markedly improved treatment of this disease, a discussion of specific recommendations that would generate data on when novel agents can be examined in comparison to standard therapy would be important.

Presentations:

  • Dr. Clive Zent, The University of Rochester, USA (10 min.)

  • Dr. Enrico Tiacci, University and Hospital of Perugia, Italy (10 min.)

Group Discussion:

  • Possible questions to consider for this discussion: In which populations should a purine-analog based approach be compared to newer agents in front-line therapy? What algorithm makes sense for treating relapsed or refractory disease in these patients?  Should studies be designed to measure response duration or time-to-next treatment?  Are long-range studies feasible for evaluating survival with the various therapeutic strategies?

…

Break (5 minutes)

…

12:05 pm eastern

Approaches to MRD: Relationships between relapse and MRD, When and how to retreat, and Value of Surveillance

This session will last about 1 hour.

Session Moderator:

  • Dr. Farhad Ravandi, MD Anderson Cancer Center, USA

Overview of session and framework for discussion: Dr. Ravandi

Presentations:

  • Dr. Gerard Lozanski, The Ohio State University, USA; presentation on relevant assays (10 min.)

  • Dr. Robert Kreitman, NIH, USA; presentation of relevant data on moxetumomab and MRD clearance (10 min.)

  • Dr. Dai Chihara, MD Anderson Cancer Center, USA; presentation of available data on concomitant versus sequential rituximab and MRD impact (10 min.)

Discussion: Following brief presentations, Dr. Ravandi will moderate a discussion with the goals of identifying concrete areas for consensus and drafting a manuscript for publication after the conference.

…

1:05 pm eastern
Wrap-up Discussion (10 min.)

Session Moderators:

  • Dr. Michael Grever, HCLF Scientific Committee Chair; The Ohio State University, USA

  • Anna Lambertson, Hairy Cell Leukemia Foundation

Potential Topics:

  • Planning for 2022 meeting (timing, location, in person versus remote)